You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
With EMR upgrades, Penn and Rush now have structured genomic data informing clinical decision support in their precision oncology programs, but much work remains.
The phase III trial saw significant overall survival and remission rates in relapsed or treatment refractory acute myeloid leukemia cases treated with the FLT3 inhibitor gilteritinib.
A modified analogue of rucaparib is being used to track PARP-1 expression in PARP inhibitor-treated patients with pancreatic, breast, prostate, and other cancer types.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
Maintenance treatment with Clovis' rucaparib may be a more tolerable maintenance therapy than chemo in platinum-responsive patients with mutations in BRCA1/2 or PALB2.